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ABSTRACT
Acetate, together with other short chain fatty acids has been implicated in 
colorectal cancer (CRC) prevention/therapy. Acetate was shown to induce apoptosis 
in CRC cells. The precise mechanism underlying acetate transport across CRC cells 
membrane, that may be implicated in its selectivity towards CRC cells, is not fully 
understood and was addressed here. We also assessed the effect of acetate in CRC 
glycolytic metabolism and explored its use in combination with the glycolytic inhibitor 
3-bromopyruvate (3BP). We provide evidence that acetate enters CRC cells by the 
secondary active transporters MCT1 and/or MCT2 and SMCT1 as well as by facilitated 
diffusion via aquaporins. CRC cell exposure to acetate upregulates the expression of 
MCT1, MCT4 and CD147, while promoting MCT1 plasma membrane localization. We 
also observed that acetate increases CRC cell glycolytic phenotype and that acetate-
induced apoptosis and anti-proliferative effect was potentiated by 3BP. Our data 
suggest that acetate selectivity towards CRC cells might be explained by the fact 
that aquaporins and MCTs are found overexpressed in CRC clinical cases. Our work 
highlights the importance that acetate transport regulation has in the use of drugs 
such as 3BP as a new therapeutic strategy for CRC.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common 
cancers and cause of cancer death in developed countries, 
highlighting the need of novel strategies for prevention/
therapy of CRCs [1].
Short chain fatty acids (SCFA), namely acetate, 
propionate and butyrate are produced by bacterial 
fermentation of dietary fiber that escape absorption in 
the small intestine. These compounds are produced in a 
millimolar ratio of approximately 60:20:20, respectively 
[2], being a major source of energy for colonocytes. It was 
shown that in vivo administration of Propionibacterium 
freudenreichii significantly increased apoptosis 
in colon cells damaged with a carcinogenic agent 
(1,2-dimethylhydrazine) without affecting the survival 
of healthy normal colonocytes [3, 4]. We and others, 
previously established that acetate affects CRC cells 
survival in vitro [5–9]. We showed that acetate inhibits 
CRC cell proliferation, induces apoptosis, promotes 
lysosomal membrane permeabilization with release of 
cathepsin D, which is associated with an autophagy-
independent degradation of damaged mitochondria [5, 
9]. The reason for acetate selectivity towards transformed 
colon cells without affecting normal colon cells is still 
elusive.
To exert their cellular effect, SCFA must be 
transported across the plasma membrane [10]. SCFA 
(including acetate) can either enter normal colon cells 
through passive diffusion or by membrane transporters 
mainly monocarboxylate transporter-1 (MCT1) and 
sodium-coupled monocarboxylate transporter SMCT1 
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[1, 11]. In CRC cells, the majority of the reports studied 
butyrate transport and showed that MCT1 is the main 
implicated transporter [1, 12, 13]. However, the precise 
mechanism of acetate transport in CRC cells has not been 
characterized and might contribute to its selectivity to 
CRC cells.
MCT overexpression has been described in several 
cancer types, including CRC, being involved in the 
maintenance of glycolytic metabolism by mediating 
lactate export [14, 15]. MCTs have been explored as 
therapeutic targets [16] and as mediators of the entry of 
drugs such as the anticancer compound 3-bromopyruvate 
(3BP) [14, 17].
Since acetate is the most relevant SCFA produced 
in the colon, although less studied, we aimed herein to 
characterize the mechanism of acetate transport across 
the plasma membrane of CRC cells. We also intended to 
evaluate the effect of acetate on glycolytic metabolism, as 
well as to explore the use of acetate in combination with 
3BP as a novel therapeutic strategy in CRC.
RESULTS
Kinetics and energetics of acetate transport by 
colorectal cancer cells
The initial uptake rates of [14C] acetate were 
evaluated in HCT-15 and RKO cell lines at pH 6.0 (Figure 
1a and 1b). The analysis of non-linear regression showed 
that in HCT-15 cells, acetate transport follows a second 
order kinetics with an affinity constant (Km) of 1.97 ± 0.57 
mM and a transport capacity (Vmax) of 62 ± 9 nmol/mg of 
protein/min. In RKO cells, acetate transport follows a first 
order kinetics with a diffusion constant of 5.19 ± 0.16 μL/
mg of protein/min.
To evaluate the energetics of [14C] acetate transport 
we tested the influence of agents known to disrupt 
different ion membrane electrochemical potentials such 
as CCCP (a protonophore which disrupts both the proton 
and the electrical gradient), monensin (an ionophore that 
specifically disrupts sodium gradient) and valinomycin 
(an ionophore which preferentially affects potassium and 
sodium gradient across biological membranes). We also 
tested the inhibition of acetate transport using inhibitors 
of monocarboxylate transporters such as CHC (inhibitor 
of MCT1 and SMCT1) [18, 19], DIDS (inhibitor of MCTs 
and anion exchangers) [20] and AR-C155858 (inhibitor of 
MCT1 and MCT2) [21] (Figure 1c).
Our results showed that CCCP inhibited significantly 
acetate transport in both HCT-15 (71%) and RKO (52%) 
cells; monensin also inhibited acetate uptake in HCT-
15 (78%) and RKO (36%), and valinomycin presented 
only a small inhibitory effect in both cell lines (22% and 
21% in in HCT-15 and RKO cells, respectively). The 
results obtained with CCCP inhibitory effects led us to 
conclude that acetate transport in CRC cells is sensitive 
to the plasma membrane potential. Moreover, monensin 
inhibition indicates that sodium gradient is also important 
in this process. Concerning valinomycin inhibition, 
the transport of acetate is less affected suggesting that 
potassium gradient might not be involved but rather 
its effect might be due to the disruption of the sodium 
gradient, taking into account the results with monensin.
Regarding general MCTs inhibitors: CHC inhibited 
both HCT-15 (30%) and RKO cells (35%), while DIDS 
and AR-C155858 had no inhibitory effect suggesting a 
possible contribution of at least SMCT1 in acetate uptake 
in CRC cells.
The transport of acetate in normal colon cells has 
also been shown to occur through passive transport [11]. 
This transport component may be relevant in RKO cells, 
since acetate transport followed a first order kinetics and 
was less affected by CCCP and monensin than HCT-15 
cells. A possible contribution of aquaporins to acetate 
uptake could also explain the acetate kinetics in RKO cells. 
Aquaporins are small transmembrane channel proteins 
that allow the passage of water and other small solutes, 
such as glycerol and some ions, through cell membranes 
in response to osmotic gradient [22, 23]. Furthermore, 
aquaporin 1 and aquaporin 3 are upregulated in CRC cells 
and their expression was correlated with tumor growth, 
invasiveness and metastasis [22, 24]. Consequently, 
we used HgCl2, which is described as an inhibitor of 
aquaporin activity (especially of certain classes such as 
aquaporin 1 and aquaporin 3) [23, 25] to verify if acetate 
transport into CRC cells could also be mediated through 
passive transport by aquaporins. Interestingly, HgCl2 
inhibited acetate uptake in HCT-15 (51%) and RKO (56%) 
cells, suggesting the contribution of aquaporins to acetate 
transport in both CRC cell lines (Figure 1c). We further 
investigated if inhibition of acetate transport by HgCl2 in 
HCT-15 and RKO cells was independent of the inhibition 
detected for CCCP or monensin. To this end we assess the 
effect of the combined used of the inhibitors. However, in 
order to avoid saturation and enable the evaluation of the 
combined effect of the different drugs, the concentrations 
of the inhibitors used in these combination experiments 
were lower than the concentrations used in the experiments 
were they were tested alone (Figures 1 and 3). Our results 
showed that while the use of CCCP (1 μM), HgCl2 (5 μM) 
and monensin (20 μM) (Figure 2a) caused inhibition of 
acetate transport in HCT-15 cells of 34%, 37%, and 69%, 
respectively, the dual combination of CCCP/HgCl2, HgCl2/
monensin, and CCCP/monensin resulted in an inhibition 
of 56%, 76% and 75%, respectively.
In RKO cells (Figure 2b) acetate uptake inhibition 
by CCCP, HgCl2 and monensin was 37%, 28% and 68%, 
respectively, but when CCCP/HgCl2, or monensin/ HgCl2 
were combined acetate transport inhibition was 46% and 
81%, respectively.
Altogether these results point to the involvement 
of a secondary active transport dependent on the 
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electrochemical Na+ gradient (probably involving 
SMCT1) and a passive transport by a facilitated diffusion 
component mediated through aquaporins in CRC cells.
Acetate upregulates the expression of MCT1, 
MCT4 and CD147 in colorectal cancer cells
We further assessed the kinetics and energetics 
of acetate uptake in cell cultures exposed with levels 
of acetate mimicking its intestinal microenvironment 
concentration. To test this hypothesis, HCT-15 and RKO 
cells were exposed for 48 hours to IC30 and IC50 doses of 
acetate previously determined by us [5].
Upon incubation with IC30 during 48 hours we 
could observe that acetate transport, in contrast to cells 
non-exposed to acetate, was significantly inhibited by 
AR-C155858 in HCT-15 and RKO cells (29% and 23%, 
respectively). This specific inhibitory effect suggests the 
involvement of MCT1 and/or MCT2 in acetate uptake 
under these conditions. In addition, the inhibitory pattern 
for CCCP, monensin and HgCl2 was not altered (Figure 3). 
The relative values of acetate transport were expressed as 
percentage in relation to the control (without inhibitor) 
in each condition. Moreover, no significant alteration in 
acetate uptake capacity was observed between cells treated 
and untreated with acetate (data not shown).
Figure 1: Characterization of acetate uptake in CRC cells. a, b. Plots of the initial uptake rates of labeled acetate, as a function of 
the acid concentration at pH 6.0 in HCT-15 (a) and RKO (b). Kinetic parameters, as affinity constant (Km) and transport capacity (Vmax) or 
Diffusion constant (Kd) for the uptake of acetate were based on the non-linear regression for the Michaelis-Menten equation f [V]=(Vmax 
x [Acetate])/(Km + [Acetate]) and Passive diffusion equation f[V] = Kd.[Acetate]. In HCT-15 the transporter system shows a Km of 1.97 ± 
0.57 mM and a Vmax of 62 ± 9 nmol/ mg of protein/ min. In RKO acetate enters cells by passive diffusion with a Kd of 5.19 ± 0.16. (c) Effect 
of CCCP (100 μM), Monensin (100 μM), Valinomycin (100 μM), AR-C155858 (1 μM), CHC (10 mM), DIDS (1 mM) and HgCl2 (100 μM) 
in the uptake of 1 mM of acetate. Statistical analysis was performed by two-way ANOVA: ***, ** and * indicate significant differences 
with a respective P-values of <0.001, <0.01 and <0.05 (n=3).
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We further assessed the expression profile of 
SMCT1, MCT1, MCT4, MCT2 and of the chaperone 
cluster of differentiation CD147 (an important protein for 
MCT activity, including MCT1 and MCT4) in response 
to acetate (Figure 4). Extracts of CRC cells exposed to 
IC30 and IC50 acetate doses for 24 and 48 hours, were 
analyzed by Western blot. We found that the expression 
of SMCT1 and MCT2 was not affected by exposure to 
acetate. In contrast the expression of MCT1 and MCT4 
was enhanced only after 48 hours, in both cell lines 
compared to the negative control. Furthermore, the 
chaperone CD147, was present in both fully-glycosylated 
(FG) and core-glycosylated (CG) forms in both CRC cell 
lines after 48 hours of acetate treatment. We have also 
observed that in both cells the expression of GLUT-1 
transporter, responsible for basal glucose transport [26], 
Figure 2: Inhibition of 1 mM of acetate uptake by CCCP (1 μM), HgCl2 (5 μM) and Monensin (20 μM) alone or in 
combination in HCT-15 a. and RKO b. cells. Statistical analysis was performed by two-way ANOVA (n=3): **** ***, ** and * 
indicate significant differences with a respective P-values of <0.0001 <0.001, <0.01 and <0.05 compared to negative control and ###, ##, 
# indicates P-values of <0.001, <0.01 and <0.05 compared to HgCl2 inhibition alone with combination (HgCl2 with CCCP and HgCl2 with 
Monesin).
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was not affected. Overall our results suggest that in CRC 
cells acetate upregulates the expression of MCT1, MCT4 
and CD147.
Acetate induces MCT1 plasma membrane 
localization in colorectal cancer cells
We further analyzed by immunofluorescence the 
changes induced by acetate on the cellular localization of 
MCT1, MCT4 and CD147. We could observe that acetate 
leads to an elevated expression of these transporters and an 
increase in MCT1 localization at the plasma membrane in 
comparison to the cytoplasm in both cell lines (Figure 5). 
Moreover, we found no differences between MCT4 and 
CD147 co-localization after acetate treatment. Our results 
suggest that in the presence of acetate, at concentrations 
similar to those observed in the colon, there is an increase 
in MCT1 localization at the plasma membrane, which 
might enhance the membrane transport of acetate by 
MCT1 in CRC cells.
Acetate treatment perturbs the glycolytic 
metabolism and 3-bromopyruvate potentiates 
acetate-induced apoptosis in colorectal cancer 
cells
We therefore wondered if acetate might induce 
metabolic changes. HCT-15 and RKO cells were exposed 
to IC30 and IC50 doses of acetate and the relative rate of 
glucose consumption and extracellular lactate production 
were measured at 3, 6, 12 and 24 hours in triplicate and 
normalized to cell biomass determined by SRB at T0 
(Figure 6a). None of these conditions showed alteration 
in cell proliferation. We found that CRC cells in response 
Figure 3: Inhibition of acetate (1 mM) uptake in HCT-15 and RKO cell lines treated with IC
30
 of acetate for 48h with 
CCCP (100 μM), Monensin (100 μM), AR-C155858 (1 μM) and HgCl2 (100 μM). Statistical analysis was performed by two-
way ANOVA: ***, ** and * indicate significant differences with a respective P -values of <0.001, <0.01 and <0.05 (n=3).
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to acetate exhibited a higher consumption of glucose (p > 
0.05) and lactate production rates (p > 0.05; p > 0.01) up 
to 24 hours in a dose-dependent manner (Figure 6b, 6c).
We have previously showed that butyrate at 
concentration ranging from at 500 – 10.000 μM increased 
MCTs expression and localization to the plasma membrane 
sensitizing breast cancer cells to the glycolytic inhibitor 
3-bromopyruvate (3BP) [17, 27]. Since acetate, like 
butyrate exhibited a similar effect in CRC cells regarding 
the expression of MCT1 and MCT4 and the increased 
CRC cell glycolytic phenotype, we hypothesized that 
acetate could also sensitize CRC cells to 3BP. To explore 
this hypothesis, we studied the combined use of acetate 
with 3BP. We performed colony formation assays (CFA) 
in CRC cells treated with 3BP IC25 and IC50 alone or in 
combination with acetate IC50. We found that the combined 
treatment (IC25 of 3BP/IC50 of acetate and IC50 of 3BP/IC50 
of acetate) decreased cell proliferation (number of colonies 
formed) in both CRC cell lines (Figure 7a). Analysis of 
cell proliferation by SRB assay (Figure 7b) showed that 
for all conditions tested, except for the IC25 of 3BP, there 
was a significant reduction in the proliferation of HCT-15 
and RKO. The combination of IC25/IC50 3BP with the IC50 
acetate significantly potentiates the effect of acetate per se 
in the inhibition of cell proliferation (p > 0.01 and p > 
0.0001, respectively) in both CRC cell lines.
We show that treatment with 3BP alone induced a 
significant increase (p > 0.05 and p > 0.01) in cells stained 
with AV/PI in a dose-dependent manner in both CRC cells. 
In addition, we found that the combined treatment of 3BP 
and acetate (IC25 of 3BP/IC50of acetate and IC50 of 3BP/
IC50 of acetate) potentiates apoptosis, as the number of 
early and late apoptotic cells showed a significant increase 
in comparison with acetate alone (p > 0.01 and p > 0.001) 
in both CRC cells. In summary, our results show that 3BP 
in combination with acetate increased the anti-proliferative 
effect of acetate and potentiates acetate-induced apoptosis 
in CRC cells.
DISCUSSION
Acetate is the main SCFA produced by 
Propionibacterium which normally reside in the human 
colon. It has been shown that the concentration of SCFA, 
including acetate, is modulated by numerous factors such 
as intestinal microbial community, diet, age, medication 
and intestinal diseases [28, 29]. The colonic SCFA 
acetate can be found in the gut at considerably high 
Figure 4: Characterization of MCTs expression and other glycolytic markers in CRC cells after acetate treatment. 
HCT-15 and RKO cells were incubated with acetate (45 mM and 70 mM for HCT-15 cells; 75 mM and 110 mM for RKO cells, respective 
doses for the IC30 and IC50) or with fresh medium (as negative control) for 24 and 48 hours. Western blotting images of the SMCT1, 
MCT1, MCT4, MCT2, CD147 and GLUT-1 expression. β-actin was used as loading control. A representative experiment of at least three 
independent experiments is shown.
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concentrations, which physiological levels range from 
40–80 mM, although there is a variation along the human 
colon and specially after a dietary fiber-containing meal 
[8, 30].
SCFAs, including acetate, show anti-tumorigenic 
properties in CRC cells and transformed colon cells, 
while exerting a protective role in normal colonic crypts 
[3, 4]. The cellular and molecular mechanisms underlying 
acetate-induced apoptosis in CRC cells have been studied 
[5, 9, 31], however the reason for acetate selectivity 
towards transformed colon and CRC cells is still elusive. 
To exert its effects and access the cellular targets, acetate 
has to be transported across the plasma membrane of 
colon cells. Studies on SCFA in normal colon and CRC 
Figure 5: Localization of MCT1, MCT4 and CD147 in CRC cells after acetate treatment. HCT-15 and RKO cells were 
incubated with acetate (45 mM and 70 mM for HCT-15 cells; 75 mM and 110 mM for RKO cells, respective doses for the IC30 and IC50) 
or with fresh medium (as negative control) for 48 hours. Representative images of immunofluorescence are shown (400× magnification).
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cells have been focused mainly on butyrate transport [1, 
12, 13], being the information on acetate transport quite 
scarce.
In an attempt to characterize the transport of 
acetate across CRC cells, here we carried out kinetics 
and energetic studies of acetate uptake. We demonstrated 
that at pH 6.0 (similar to the gut environment), acetate 
transport across CRC cell membrane is strongly 
inhibited by monensin and CHC but not by DIDS and 
AR-C155858, supporting the contribution of SMCT1 
in acetate transport in CRC cells. SMCT1 is an active 
unidirectional transporter that mediates lactate uptake 
and is expressed abundantly in the apical membrane of 
the colon [12, 32, 33]. Our results on acetate transport are 
in accordance with several reports showing that SMCT1 
transports monocarboxylic acids such as butyrate, 3BP 
and dichloroacetate in cancer cells [17, 34–36]. On the 
other hand, some reports have demonstrated that SMCT1 
is silenced in some CRC by DNA methylation [1, 12, 34, 
36], conferring a selective advantage to escape butyrate-
induced cell death [12, 37]. This could also be true for 
acetate as here we showed that in CRC cells expressing 
SMCT1, this transporter is relevant for acetate uptake and 
consequently for the acetate-induced apoptosis effect in 
CRC cells.
Acetate was also demonstrated to enter normal 
colon cells by passive transport [11]. Our experimental 
data suggest that diffusion through aquaporins, small 
transmembrane channel proteins [24, 38, 39], also 
contributes to acetate uptake, since acetate transport 
was inhibited by HgCl2. The contribution of aquaporins 
to acetate uptake could explain the different kinetics 
of acetate transport in the CRC cells studied. Indeed, 
acetate transport follows a first order kinetics in RKO 
cells, being less affected by CCCP or monensin than 
HCT-15 cells, likely due to a higher contribution of 
aquaporins for acetate transport in RKO cells. To the best 
of our knowledge, this is the first report suggesting that 
aquaporins, found upregulated in different types of cancer 
including CRC [22, 24, 40], might play a role in acetate 
transport in CRC cells.
Monocarboxylate transporters 1 to 4 (MCT 1-4) are 
proton symporters, involved in the uptake and/or efflux 
of pyruvate, lactate, ketone bodies and SCFA through the 
plasma membrane [11, 15]. We investigated if exposure 
to acetate could regulate its transport through MCTs. 
Figure 6: Acetate induces metabolic changes in CRC cells. HCT-15 and RKO cells were incubated with acetate (45 mM and 
70 mM for HCT-15 cells; 75 mM and 110 mM for RKO cells, respective doses for the IC30 and IC50) or with fresh medium (as negative 
control). a. Effect of acetate on cell proliferation, determined by SRB assay. HCT-15 and RKO cells were seeded at a density of 7x104 and 
5x104 cells/well respectively and incubated with sodium acetate (3, 6, 12 and 24 hours). As positive control was used 500 uL and 1 mM 
H2O2, respectively for HCT-15 and RKO cells. As negative control cells were incubated with fresh complete medium. For each bar, the 
mean for at least three independent experiments is represented (Bonferroni’s test; *** p ≤ 0.001 compared to control cells). (Continued )
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Figure 6: (Continued ) Acetate induces metabolic changes in CRC cells. b. Extracellular amounts of glucose consumption and c. 
lactate production overtimes 3, 6, 12 and 24 hours are shown. Values are expressed as mean ± SD of at least three independent experiments. 
*P ≤ 0.05 and **P ≤ 0.01 compared with control cells.
Figure 7: Effect of acetate with 3-bromopyruvate (3BP; a glycolysis inhibitor) in CRC cells. a, b and c. CRC cells were 
treated with IC25 and IC50 values for the 3BP (17.5 uM, 35 uM and 75 uM, 150 uM, respectively for HCT-15 and RKO cells). The treatments 
were performed with 3BP alone or with acetate treatment combination (only the IC50 value for the acetate: 70 mM for HCT-15 and 110 
mM for RKO cell line) after 48 h of incubation. 3BP was added 16 hours before to complete 48 hours of the treatment. As negative control, 
cells were treated with fresh medium. H2O2 (500 uM or 1 mM for HCT-15 or RKO cell lines, respectively) was used as positive control. 
a. Colony formation assay during 14 days shows that the combined treatment (IC25 of 3BP/IC50 of acetate and IC50 of3BP/IC50 of acetate) 
decreases cell proliferation (number of colony formed at the end of the assay) in both CRC cell lines in a dose-dependent manner compared 
to the negative control and with the same dose of the 3BP or acetate alone. (Continued )
Oncotarget10www.impactjournals.com/oncotarget
Using the inhibitor AR-C155858, we showed, that 
MCT1 and/or MCT2 participate actively in the transport 
of acetate across the membrane in CRC cells exposed to 
physiological doses of acetate. These observations are 
in accordance with the transport of butyrate into colon 
cancer cells mainly by MCT1 [1, 13, 41]. Moreover, 
MCT1 was also reported to be responsible for acetate 
transport in mouse cancer cells (Ehrlich-Lettre ascites 
cells) [42].
Despite some controversies in the literature, 
MCT1, MCT2 and MCT4 are found upregulated in 
CRC compared to normal epithelium [15, 43, 44]. There 
are different mechanisms involved in the regulation of 
MCTs, however their regulation by SCFA (especially 
acetate) needed further clarification [1, 12, 13, 41]. It 
has been shown that upon butyrate treatment, MCT1 
is the most abundant MCT isoform expressed in the 
CRC Caco-2 cells [13]. Our data show that exposure 
to acetate increased the expression of MCT1, MCT4 
and the glycosylated CD147, associated with MCT1 
re-localization to the plasma membrane of CRC cells. 
Indeed, MCT1 and MCT4 require association with 
CD147 for proper plasma membrane localization and 
function [18]. Our results put forward a possible role 
of acetate in the regulation of its uptake/transport, both 
by controlling the expression of MCTs and CD147, 
with consequent MCT1 functionalization at the plasma 
membrane in CRC cells.
Figure 7:  (Continued ) Effect of acetate with 3-bromopyruvate (3BP; a glycolysis inhibitor) in CRC cells. a, b and c. 
b. Sulforhodamine B (SRB) assay analyzes the cell proliferation of the same conditions. Values represent mean ± SD of at least three 
independent experiments. **P ≤ 0.01, ***P ≤ 0.001 and ***P ≤ 0.0001 compared with negative control cells and ## P ≤ 0.01 and #### P 
≤ 0.0001 comparing acetate alone with combined treatment (IC25 of 3BP/IC50 of acetate and IC50 of3BP/IC50 of acetate). c. Quantitative 
analysis of AV/PI staining in HCT-15 and RKO cells. Values represent mean ± SD (AV – PI -, AV + PI -, AV + PI + and AV – PI +) of each 
condition (n=3). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ***P ≤ 0.0001 compared with negative control cells and ## P ≤ 0.01 and #### P 
≤ 0.0001 comparing acetate alone with combined treatment (IC25 of 3BP/IC50 of acetate and IC50 of3BP/IC50 of acetate).
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Most cancer cells, including CRC, exhibit a 
hyper-glycolytic phenotype, which is characterized by 
production of high amounts of lactate, contributing to 
acidification of the tumor microenvironment [15, 45]. As 
glucose becomes the primary source in CRC cells, glucose 
transporters (GLUTs) and MCTs have a central role in the 
maintenance of the cancer cell glycolytic metabolism [14, 
46]. Here, we observed that acetate induces expression of 
both MCT1 and MCT4 over time, without changes in the 
levels of GLUT1, the main glucose transporter expressed 
in CRC [16, 41, 47]. Furthermore, upon acetate treatment, 
we observed an increase in glucose consumption and 
lactate production up to 24h in CRC cells, which goes in 
line with the increased expression of MCTs and the need 
to export the produced lactate [48–51]. Our findings are in 
agreement with Matthews et al, describing that butyrate 
and propionate, alone or in combination, significantly 
increased glucose consumption. The authors explained 
the elevated glucose consumption rates, mediated 
by an increase in oxidative pentose pathway activity 
(important pathway of glucose metabolism), as a way to 
produce energy efficiently [6]. In addition, the increase 
on glucose consumption and lactate production after 
acetate treatment may be correlated with our previous 
reports showing that acetate treatment is associated 
with mitochondria dysfunctions, such as an increase in 
mitochondrial mass, an accumulation of superoxide anion 
and a decrease in mitochondrial membrane potential, 
even after short incubation times (12 and 24 hours after 
acetate treatment) [9]. The increase in glucose uptake/
consumption by CRC cells after 24 hours of acetate 
exposure may therefore reflect a response that cells convey 
to cope with acetate-induced mitochondrial dysfunction 
and consequently oxidative phosphorylation impairment. 
Indeed, mitochondria dysfunction induced by acetate 
might contribute to the observed switch to the glycolytic 
metabolism up to 24 hours in CRC cells.
Due to MCTs overexpression in cancer and important 
role in the maintenance of glycolytic metabolism [14, 
43], MCTs became attractive targets in cancer therapy, 
especially in cancers with a hyper-glycolytic phenotype like 
CRC [14, 46]. However, they can also be used to transport 
of drugs into cancer cells, behaving as “Trojan horses” [17, 
52]. In fact, MCTs are described to mediate the entry of 
the chemotherapeutic agent 3BP used to selectively kill 
cancer cells [14, 17]. In this context, it was demonstrated 
that butyrate mediated-increase in MCTs expression and 
plasma membrane localization sensitizes breast cancer cells 
to 3BP [17, 27]. Since acetate exhibited a similar effect on 
MCT expression in CRC cells, we hypothesized that acetate 
could also sensitize CRC cells to 3BP. Our results showed 
that, in comparison to the effect of acetate or 3BP alone, 
the combination of both compounds is more effective in the 
inhibition of cell proliferation and induction of apoptosis 
in CRC cells, which might have important implications in 
CRC therapy.
Summing up, we show that acetate uptake involves 
at least two distinct mechanisms of transport in CRC cells 
namely mediated by SMCT1, MCT1 and/or MCT2 and 
passive transport by aquaporins. In addition, we found that 
acetate upregulates MCT1, MCT4 and CD147, with re-
localization of MCT1 at the plasma membrane, associated 
with an increase in the glycolytic phenotype.
Our data showing an important role of MCTs and 
aquaporins in acetate uptake, consistently with reported data 
on MCTs and aquaporins overexpression in CRC clinical 
cases, may underlie acetate selectivity towards CRC cells.
Finally, we identified a novel approach for CRC 
therapy, based on the elimination of CRC cells exposed 
to acetate, through their sensitization by 3BP or another 
glycolytic inhibitor whose transport is mediated by 
MCTs.
MATERIALS AND METHODS
Material
Reagents
Sodium acetate and HgCl2 were purchased from 
Merck. Radiolabelled [14C] acetate (specific activity 
of 55.2 mCi/mmol) from PerkinElmer. Carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP), monensin, 
valinomycin and α-cyano-4-hydroxycinnamic acid (CHC) 
from Sigma. 4,4’-Di-isothiocyano-2,2’-stilbenedisulfonic 
acid (DIDS) was obtained from Santa Cruz Biotechnology 
and AR-C155858 was a gift from AstraZeneca.
Cell lines
Human colorectal cancer (CRC) cell lines, HCT-15 
and RKO were obtained from the American Type Culture 
Collection (ATCC). Cells were cultured at 37 °C under a 
humidified atmosphere containing 5% CO2. HCT-15 cells 
were grown in Roswell Park Memorial Institute (RPMI) 
medium and RKO cells in Dulbecco’s Modified Eagle 
Medium (DMEM).
All culture media were supplemented with 10% fetal 
bovine serum and 100 U/ml penicillin/streptomycin.
Methods
Acetate uptake assay
The protocol for [14C] acetate uptake used was 
described previously [17]. For normalization, protein 
was quantified using a BCA Protein Assay Kit (Pierce). 
As [14C] acetate uptake was linear up to 5 min, 3 min 
of incubation was used. The effect of inhibitors: AR-
C155858, CHC, DIDS, CCCP, monensin, valinomycin 
and HgCl2 was evaluated in cells incubated for 3 min with 
each compound in MES buffer, pH 6.0, prior to incubation 
with 1.0 mM [14C] acetate for 3 min.
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Western blotting assay
Cells were seeded in 6-well plates and exposed to 
acetate for 48 hours: 45 mM, 70 mM for HCT-15 and 75 
mM, 110 mM for RKO cells (IC30 and IC50 acetate doses 
for both cell lines) previously determined by us [5]. As 
negative control, cells were incubated with fresh medium. 
Cell lysis, total protein and Western blotting were carried 
out as previously described [5].
The primary antibodies used were: anti-MCT1 
(1:500), anti-MCT2 (1:200), anti-MCT4 (1:500), anti-
SMCT1 (1:250), anti-CD147 (1:500), and anti-actin 
(1:5000), from Santa Cruz Biotechnology; anti-GLUT 1 
(1:200) (Abcam). Chemiluminescence was detected using 
the ECL detection system (Amersham) and the imager 
Chemi-Doc XRS system (Bio-Rad).
Immunofluorescence assay
CRC cells were seeded in 12-well plates containing 
glass coverslips and exposed to acetate during 48 hours 
(IC30 and IC50 acetate doses) for the cellular localization 
of MCT1, MCT4 and CD147. The immunofluorescence 
protocol used was described previously [53]. At the 
end, coverslips were mounted on Vectashield mounting 
medium with DAPI and observed under a fluorescence 
microscope (Olympus BX61 fluorescence microscope). 
Three coverslips were prepared for each experimental 
condition.
Determination of glucose consumption and lactate 
production
Cells cultured in 48-well plates were pre-incubated 
in glucose-free media for 2 h, cells were washed with PBS 
and incubated with acetate (IC30 and IC50, as mentioned 
before). Conditioned medium of non-treated cells 
(negative control) or exposed to acetate was collected at 3, 
6, 12 and 24 hours. Glucose consumption and extracellular 
lactate were measured by the enzymatic colorimetric kits: 
Glucose Assay Kit (Roche, Mannheim, Germany) and 
Lactate Assay kit (SpinReact) Fluorescence intensity was 
detected with absorbance emission at 490 nm. Values 
are expressed as the mean of fluorescence intensity 
normalized to T0 (control for glucose and lactate levels 
before the treatment with acetate) and the cell biomass was 
analyzed by Sulforhodamine (SRB) assay as previously 
described [5].
Sulforhodamine (SRB) assay
The IC50 concentrations of 3-bromopyruvate (3BP) 
were calculated by the SRB assay as previously described 
[5]. The following 3BP doses were used: 17.5 μM, 35 μM 
and 75 μM, 150 μM; IC25 and IC50, respectively for HCT-
15 and RKO cells). For the SRB assay with acetate and 
3BP, 3BP was co-incubated 16 hours before completing 48 
hours of acetate treatment. Briefly, HCT-15 and RKO were 
seeded in 24-well and incubated 48 hours with 70 mM 
and 110 mM of acetate (IC50 for HCT-15 and RKO cells, 
respectively) previously determined [5] with and without 
previous co-incubation with the IC25 and IC50 doses of 3BP 
for 16 h. As negative control cells were incubated with 
fresh medium and as positive control we used H2O2 (500 
mM or 1 mM for HCT-15 or RKO cell lines, respectively). 
All samples were measured in triplicates and the values 
were expressed relative to the negative control.
Colony formation assay (CFA)
Cells were seeded in 6-well plates at 600 cells/
mL, 300 cells/mL (respectively for HCT-15 and RKO 
cell lines) and were treated as described for the SRB 
assay (same conditions). After 48 hours of treatment, the 
medium was replaced by fresh medium twice per week 
during 14 days. To evaluate the colony numbers formed 
for each condition, cells were washed with PBS and fixed 
with 6% glutaraldehyde/0.5% crystal violet solution for 
30 min, at RT. The cells were then washed with water and 
air-dried.
Apoptosis assay
Cells were seeded in 6-well plates and were treated 
as described above for the SRB assay (same conditions). 
The percentage of cells undergoing apoptosis after 48 h 
of acetate treatment was determined using Annexin-V 
FITC (AV) (BD Biosciences) and Propidium iodide (PI) 
(Sigma). Both floating and attached cells were collected 
and prepared as described previously [5]. Cell viability 
and cell death was assessed by double staining with 
Annexin-V FITC/ PI. Unstained and stained cells were 
classified as follows: viable cells (AV-/PI-), early apoptotic 
cells (AV+/PI-), late apoptotic cells (AV+/PI+) or necrotic 
cells (AV-/PI+).
Statistical analysis
Kinetic parameters were determined using Prism 
software version 6 (GraphPad) for the non-linear 
regression of the values of the initial uptake rates of 
acetate as a function of the acid concentration. Other 
statistical significance analysis were determined by two-
way ANOVA or one-way ANOVA followed by Dunnett 
or Bonferroni’s test for multiple comparisons. All results 
are presented as mean ± standard deviation (SD) of three 
independent experiments. Differences were considered 
significant for P values lower than 0.05.
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